Advertisement

Digestive Diseases and Sciences

, Volume 60, Issue 4, pp 1045–1051 | Cite as

Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir

  • Kevin P. Vo
  • Philip Vutien
  • Matthew J. Akiyama
  • Vinh D. Vu
  • Nghiem B. Ha
  • Joy I. Piotrowski
  • James Wantuck
  • Marina M. Roytman
  • Naoky Tsai
  • Ramsey Cheung
  • Jiayi Li
  • Mindie H. Nguyen
Original Article

Abstract

Background

There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort.

Aims

In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort.

Methods

We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic.

Results

Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the “80/80/80 rule,” diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8–6.06, P < 0.001).

Conclusion

SVR was much lower in a real-life patient cohort than in clinical trials (53 % for TVR and 40 % for BOC, compared to 66–75 % in clinical trials).

Keywords

HCV Routine practice Effectiveness PEG-IFN TVR BOC 

Abbreviations

HCV

Hepatitis C virus

SVR

Sustained virological response

PEG-IFN + RBV

Pegylated interferon and ribavirin

RCT

Randomized controlled trial

ITT

Intention-to-treat

EVR

Early virological response

Notes

Conflict of interest

Kevin P. Vo, Philip Vutien, Matthew J. Akiyama, Vinh D. Vu, Nghiem B. Ha, Joy I. Piotrowski, and James Wantuck have none to declare. Marina M. Roytman is on Gilead speakers’ bureau and advisory board. Naoky Tsai discloses research grants with AbbVie, Janssen, Gilead Sciences, BMS, and Beckman. Naoky Tsai discloses he is on the Speaker’s bureau for AbbVie, Janssen, Gilead Sciences, BMS, Salix, and Bayer, and is also on the advisory board for Gilead Sciences and AbbVie. Ramsey Cheung discloses research grants with Gilead Sciences. Jiayi Li discloses he is a speaker for Gilead Sciences. Mindie H. Nguyen discloses she has received honoraria and research support from Bristol-Myers Squibb, Gilead Sciences, and Janssen Pharmaceuticals.

References

  1. 1.
    Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in the USA: an estimate of true prevalence. Liver Int. 2011;31:1090–1101.CrossRefPubMedGoogle Scholar
  2. 2.
    Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–1861.CrossRefPubMedGoogle Scholar
  3. 3.
    Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(509–516):e1.PubMedGoogle Scholar
  5. 5.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.CrossRefPubMedGoogle Scholar
  6. 6.
    Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–1601.CrossRefPubMedGoogle Scholar
  7. 7.
    Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.CrossRefPubMedGoogle Scholar
  8. 8.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.CrossRefPubMedGoogle Scholar
  9. 9.
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593.CrossRefPubMedGoogle Scholar
  10. 10.
    Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93–103.CrossRefPubMedGoogle Scholar
  11. 11.
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.CrossRefPubMedGoogle Scholar
  12. 12.
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med.. 2011;364:1195–1206.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–1444.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12:717–728.CrossRefPubMedGoogle Scholar
  15. 15.
    Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012;54:96–104.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(1450–1455):e2.PubMedGoogle Scholar
  17. 17.
    Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122–1126.CrossRefPubMedGoogle Scholar
  18. 18.
    Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis. 2009;49:1397–1401.CrossRefPubMedGoogle Scholar
  19. 19.
    Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci. 2014;59:3043–3052.CrossRefPubMedGoogle Scholar
  20. 20.
    Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther. 2013;38:124–133.CrossRefPubMedGoogle Scholar
  21. 21.
    Ollendorf DA, Tice JA, Pearson SD. The Comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Intern Med.. 2014;174:1170–1171.CrossRefPubMedGoogle Scholar
  22. 22.
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Kevin P. Vo
    • 1
  • Philip Vutien
    • 1
  • Matthew J. Akiyama
    • 5
  • Vinh D. Vu
    • 1
  • Nghiem B. Ha
    • 1
  • Joy I. Piotrowski
    • 2
  • James Wantuck
    • 1
  • Marina M. Roytman
    • 2
  • Naoky Tsai
    • 2
  • Ramsey Cheung
    • 3
  • Jiayi Li
    • 4
  • Mindie H. Nguyen
    • 1
  1. 1.Division of Gastroenterology and HepatologyStanford University Medical CenterPalo AltoUSA
  2. 2.The Queens Medical CenterUniversity of HawaiiHonoluluUSA
  3. 3.VA Palo AltoPalo AltoUSA
  4. 4.Palo Alto Medical Foundation Camino DivisionMountain ViewUSA
  5. 5.Division of Infectious DiseasesNew York University School of MedicineNew YorkUSA

Personalised recommendations